We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 6147K
Advanced Oncotherapy PLC
03 September 2021
3 September 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Update on admission of Subscription Shares
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the announcements released by the Company on 11 August 2021 and 31 August 2021, settlement of the Subscription that is subject to the First Admission is now expected to complete within the next two weeks. Once funds have been received in full, application will be made to the London Stock Exchange for the 82,383,761 Subscription Shares and the 6,470,880 new ordinary shares in respect of the fee arrangements set out in the Company's announcement of 11 August 2021 to be admitted to trading on AIM ("Admission").
The remaining 11,145,405 Subscription Shares that are subject to the Second Admission are expected to be admitted to trading on AIM on or around 1 October 2021.
A further announcement will be made at the appropriate time.
Total voting rights
The Company's issued share capital as at the date of this announcement comprises 350,334,730 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 350,334,730. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same meaning as in the announcement of 11 August 2021 unless otherwise defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: +44 (0) 20 3617 8728 Nicolas Serandour, CEO Allenby Capital Limited (Nomad and Joint Broker) Nick Athanas / Liz Kirchner (Corporate Finance) Tel: +44 (0) 20 3328 5656 Amrit Nahal / Matt Butlin (Sales and Corporate Broking) SI Capital Ltd (Joint Broker) Nick Emerson Tel: +44 (0) 1483 413 500 Jon Levinson Tel: +44 (0) 20 3871 4066 FTI Consulting (Financial PR & IR) advancedoncotherapy@fticonsulting.com Simon Conway / Rob Winder Tel: +44 (0) 20 3727 1000
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSSLESEEFSEEU
(END) Dow Jones Newswires
September 03, 2021 02:00 ET (06:00 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions